findmyKOL

Kathleen Moore, MD

Enriched profile

Professor, Department of Obstetrics and Gynecology; Deputy Director and Director of Phase I Clinical Trials, Fred & Pamela Buffett Cancer Center · University of Nebraska Medical Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Oklahoma City, OK · South Central · United StatesSpecialtyGynecologic OncologyFocusOvarian cancer diagnosis and treatment+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2017–2026

Kathleen Moore is Professor, Department of Obstetrics and Gynecology; Deputy Director and Director of Phase I Clinical Trials, Fred & Pamela Buffett Cancer Center at University of Nebraska Medical Center. OpenAlex indexes 1,026 publications with 47,487 citations (h-index 84); ClinicalTrials.gov lists 22 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 16 Oct 2026

Kathleen N. Moore, MD, is Professor, Department of Obstetrics and Gynecology at University of Nebraska Medical Center, Fred & Pamela Buffett Cancer Center (Omaha, NE). The public record shows 1,026 publications with 47,487 citations (h-index 84), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 41 companies, 6 NIH-funded awards (2017–2026).

  • Most recent indexed publication: 2026 · Nature reviews. Clinical oncology
  • Top research focus: Ovarian cancer diagnosis and treatment
  • 22 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 41 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer15 trialsEndometrial Neoplasms6 trialsUterine Cervical Neoplasms3 trialsCarcinoma, Adenosquamous3 trialsFallopian Tube Neoplasms3 trialsCarcinoma, Squamous Cell2 trialsSarcoma2 trialsComa2 trialsCarcinoma, Endometrioid2 trialsCarcinoma, Ovarian Epithelial2 trialsBreast Cancer1 trialCarcinoma, Small Cell1 trialPeritoneal Neoplasms1 trialAdenocarcinoma, Clear Cell1 trialCarcinosarcoma1 trialSubstance Use Disorders1 trialEndometrial Hyperplasia1 trialHyperplasia1 trialUterine Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trials1Industry payments16Publications5Opdivogeneric · NivolumabClinical trials1Industry payments1Publications3Tecentriqgeneric · AtezolizumabClinical trials1Industry payments1Publications2Elaheregeneric · Mirvetuximab soravtansineClinical trials—Industry payments14Publications4Zejulageneric · NiraparibClinical trials—Industry payments12Publications5Keytrudageneric · PembrolizumabClinical trials—Industry payments14Publications2PaclitaxelClinical trials6Industry payments—Publications5CarboplatinClinical trials4Industry payments—Publications3BevacizumabClinical trials2Industry payments—Publications3Imfinzigeneric · DurvalumabClinical trials—Industry payments2Publications3RucaparibClinical trials2Industry payments—Publications2NavicixizumabClinical trials1Industry payments—Publications1

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trials—Industry payments53Daiichi Sankyo Inc.Clinical trials—Industry payments27Merck Sharp & Dohme LLCClinical trials—Industry payments26AstraZeneca UK LimitedClinical trials—Industry payments21Abbvie Inc.Clinical trials—Industry payments16Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments16AstraZeneca Pharmaceuticals LPClinical trials—Industry payments12BioNTech SEClinical trials—Industry payments12Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments12Aadi Bioscience, Inc.Clinical trials—Industry payments11Novocure Inc.Clinical trials—Industry payments11Genmab U.S., Inc.Clinical trials—Industry payments8Daiichi Sankyo Company LTDClinical trials—Industry payments7E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments7Eisai Inc.Clinical trials—Industry payments7ImmunoGen, Inc.Clinical trials—Industry payments6Seagen Inc.Clinical trials—Industry payments6University of OklahomaClinical trials6Industry payments—Corcept TherapeuticsClinical trials—Industry payments5Gilead Sciences, Inc.Clinical trials—Industry payments5Sanofi-Aventis U.S. LLCClinical trials—Industry payments5Alkermes, Inc.Clinical trials—Industry payments3Amgen Inc.Clinical trials—Industry payments3Merck Sharp & Dohme CorporationClinical trials—Industry payments3Novartis Pharmaceuticals CorporationClinical trials—Industry payments3Novocure GmbHClinical trials—Industry payments3AstraZenecaClinical trials2Industry payments—BeiGene USA, Inc.Clinical trials—Industry payments2Blueprint Medicines CorporationClinical trials—Industry payments2Eli Lilly and CompanyClinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,026publications

Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.

47,487citations

Total citations across indexed works.

84h-index

Hirsch index (OpenAlex). i10-index 336.

Clinical & industry

trials, payments and federal funding
22clinical trials

Investigator role on registered studies.

View trials ↓
41companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
6NIH grants · 2017–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:

All 22 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

41 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 81 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Poly(ADP-Ribose) Polymerase Inhibitor100%
    Lynparza100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

6 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:

All 41 award records: search, sort and filter.Explore →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 39 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
    2,846 citations2018
    doi.org ↗
  2. 02
    Recent advances and clinical applications of deep learning in medical image analysis
    1,016 citations2022
    doi.org ↗
  3. 03
    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
    931 citations2019
    doi.org ↗
  4. 04
    Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
    561 citations2019
    doi.org ↗
  5. 05
    Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
    537 citations2019
    doi.org ↗
All 1,026 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

David M. O’Malley121Carol Aghajanian119Bradley J. Monk101Robert L. Coleman94Amit M. Oza92Premal H. Thaker74Susana Banerjee71Jalid Sehouli67Michael A. Bookman67Joan L. Walker64Sandro Pignata64Ana Oaknin61Els Van Nieuwenhuysen61Nicoletta Colombo60Austin Miller59Tashanna Myers58Robert S. Mannel58D. Scott McMeekin56Johanna C. Bendell55Ursula A. Matulonis53Michael J. Birrer52Kai Ding49Camille C. Gunderson49Manish R. Patel47Paul DiSilvestro47Erika Hamilton46Charles Anderson46Aikou Okamoto46Antonio González-Martı́n45Regina Berger45Cara Mathews43Ignace Vergote42Yvonne G. Lin42Christina Washington41Susanna V. Ulahannan41Victor K. Khor40Thomas Reid39Luciana Molinero39Suzanne F. Jones39Charles N. Landen38

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/scientific-contributions/Kathleen-N-Moore-39995420

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Other

    ocrahope.org/about/team/scientific-advisory-committee/kathleen-moore

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ocrahope.org ↗
  • Other

    unmc.edu/newsroom/2026/03/18/kathleen-moore-md-appointed-cancer-centers-deputy-director

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Apple Podcasts

    podcasts.apple.com/us/podcast/gynecologic-oncology-interview-with-kathleen-moore-md/id699146770

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University of Washington School of Medicine, Seattle, WA

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • MS in Epidemiology

    University of Oklahoma Health Sciences Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Residency in Obstetrics and Gynecology

    Magee-Womens Hospital, University of Pittsburgh Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Fellowship in Gynecologic Oncology

    University of Oklahoma Health Sciences Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Board certified in Obstetrics and Gynecology
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Board certified in Gynecologic Oncology
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Board certified in Hospice and Palliative Medicine
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗

Editorial & leadership roles

journal and society appointments
  • Society Treasurer

    ASCO Board of Directors, 2026–2027 term

    2027
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asco.org ↗
  • Member

    Board of Directors, American Society of Clinical Oncology (ASCO); began a four-year term in the Designated Surgical Oncologist seat starting June 2023

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
  • Member

    Board of Directors, GOG Foundation (Gynecologic Oncology Group Foundation)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Leadership roles within NRG Oncology

    including Chair of the Ovarian Cancer Committee, and member of the NRG/GOG Phase I Working Group and Developmental Therapeutics Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →unmc.edu ↗
  • Leadership within the International Gynecologic Cancer Research Consortia
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Member

    Scientific Advisory Committee, Ovarian Cancer Research Alliance (OCRA)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ocrahope.org ↗
  • Editorial board member for 4 academic publications
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
  • Member

    National Cancer Institute Gynecologic Cancer Steering Committee; Society of Gynecologic Oncology; Western Association of Gynecologic Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.